Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, End User, and Region - Analysis and Forecast, 2023-2033

1.1 Global Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Key Trends
1.2.1.1 Significant Number of Collaborations among Market Players
1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
1.2.2 Opportunity Assessment
1.2.3 Patent Analysis
1.2.3.1 Awaited Technological Developments
1.2.3.2 Patent Filing Trend (by Country)
1.2.3.3 Patent Filing Trend (by Year)
1.2.4 Production Capability
1.2.5 Regulatory Framework
1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
1.3.1 Pre-COVID-19 Phase
1.3.2 During COVID-19
1.3.3 Post-COVID-19 Phase
1.3.3.1 Impact on Demand and Supply
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
1.6.3 MicroRNAs (miRNAs)
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Business Dynamics
1.7.1 Impact Analysis
1.7.2 Business Drivers
1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
1.7.3 Business Restraints
1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
1.7.4 Business Opportunities
1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2.1 Opportunity Assessment
2.2 Growth-Share Matrix
2.3 Solid-Phase Oligonucleotide Synthesis (SPOS)
2.4 Liquid-Phase Oligonucleotide Synthesis (LPOS)

3.1 Opportunity Assessment
3.2 Growth-Share Matrix
3.2.1 Standard Nucleic Acid
3.2.2 Micro-Scale Nucleic Acid
3.2.3 Large-Scale Nucleic Acid
3.2.4 Custom Nucleic Acid
3.2.5 Modified Nucleic Acid
3.2.6 Primers
3.2.7 Probes
3.2.8 Other Nucleic Acid
3.2.9 Other Services

4.1 Opportunity Assessment
4.2 Growth-Share Matrix
4.3 Column-Based Method
4.4 Microarray-Based Method

5.1 Opportunity Assessment
5.2 Growth-Share Matrix
5.3 Pharmaceutical Companies
5.4 Academic Institutions
5.5 Diagnostic Laboratories

6.1 North America Nucleic Acid Therapeutics CDMO Market
6.1.1 Key Findings
6.1.2 Market Dynamics
6.1.2.1 Impact Analysis
6.1.3 Market Sizing and Forecast
6.1.3.1 North America Nucleic Acid Therapeutics CDMO Market (by Country)
6.1.3.1.1 U.S.
6.1.3.1.2 Canada
6.2 Europe Nucleic Acid Therapeutics CDMO Market
6.2.1 Key Findings
6.2.2 Market Dynamics
6.2.2.1 Impact Analysis
6.2.3 Market Sizing and Forecast
6.2.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
6.2.3.1.1 Germany
6.2.3.1.2 U.K.
6.2.3.1.3 France
6.2.3.1.4 Spain
6.2.3.1.5 Italy
6.2.3.1.6 Rest-of-Europe
6.3 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
6.3.1 Key Findings
6.3.2 Market Dynamics
6.3.2.1 Impact Analysis
6.3.3 Market Sizing and Forecast
6.3.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
6.3.3.1.1 Japan
6.3.3.1.2 China
6.3.3.1.3 India
6.3.3.1.4 Australia
6.3.3.1.5 Rest-of-Asia-Pacific
6.4 Rest-of-the-World Nucleic Acid Therapeutics CDMO Market
6.4.1 Key Findings
6.4.2 Market Dynamics
6.4.2.1 Impact Analysis
6.4.3 Market Sizing and Forecast

7.1 Competitive Benchmarking
7.1.1 Key Strategies and Developments
7.1.1.1 Funding Activities
7.1.1.2 New Offerings
7.1.1.3 Mergers and Acquisitions
7.1.1.4 Partnerships and Collaborations
7.1.1.5 Business Expansions
7.1.1.6 Regulatory and Legal Activities
7.1.2 Market Share Analysis
7.1.3 Visual Graphics of Key Companies
7.2 Company Profile
7.2.1 Agilent Technologies, Inc.
7.2.1.1 Company Overview
7.2.1.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.1.3 Financials
7.2.1.4 Recent Developments
7.2.1.5 Analyst Perspective
7.2.2 AGC Biologics
7.2.2.1 Company Overview
7.2.2.2 Role of AGC Biologics in the Global Nucleic Acid Therapeutics CDMO Market
7.2.2.3 Financials
7.2.2.4 Recent Developments
7.2.2.5 Analyst Perspective
7.2.3 Asymchem Inc.
7.2.3.1 Company Overview
7.2.3.2 Role of Asymchem Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.3.3 Financials
7.2.3.4 Recent Developments
7.2.3.5 Analyst Perspective
7.2.4 BACHEM
7.2.4.1 Company Overview
7.2.4.2 Role of BACHEM in the Global Nucleic Acid Therapeutics CDMO Market
7.2.4.3 Financials
7.2.4.4 Recent Developments
7.2.4.5 Analyst Perspective
7.2.5 BioCina
7.2.5.1 Company Overview
7.2.5.2 Role of BioCina in the Global Nucleic Acid Therapeutics CDMO Market
7.2.5.3 Recent Developments
7.2.5.4 Analyst Perspective
7.2.6 CMIC HOLDINGS Co., Ltd.
7.2.6.1 Company Overview
7.2.6.2 Role of CMIC HOLDINGS Co., Ltd. In the Global Nucleic Acid Therapeutics CDMO Market
7.2.6.3 Financials
7.2.6.4 Analyst Perspective
7.2.7 Codexis, Inc.
7.2.7.1 Company Overview
7.2.7.2 Role of Codexis, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.7.3 Financials
7.2.7.4 Recent Developments
7.2.7.5 Analyst Perspective
7.2.8 Danaher Corporation
7.2.8.1 Company Overview
7.2.8.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
7.2.8.3 Financials
7.2.8.4 Recent Developments
7.2.8.5 Analyst Perspective
7.2.9 Eurofins Scientific
7.2.9.1 Company Overview
7.2.9.2 Role of Eurofins Scientific in the Global Nucleic Acid Therapeutics CDMO Market
7.2.9.3 Financials
7.2.9.4 Recent Developments
7.2.9.5 Analyst Perspective
7.2.10 GeneOne Life Science
7.2.10.1 Company Overview
7.2.10.2 Role of GeneOne Life Science in the Global Nucleic Acid Therapeutics CDMO Market
7.2.10.3 Recent Developments
7.2.10.4 Analyst Perspective
7.2.11 Kaneka Corporation
7.2.11.1 Company Overview
7.2.11.2 Role of Kaneka Corporation in the Global Nucleic Acid Therapeutics CDMO Market
7.2.11.3 Financials
7.2.11.4 Recent Developments
7.2.11.5 Analyst Perspective
7.2.12 LGC Science Group Holdings Limited
7.2.12.1 Company Overview
7.2.12.2 Role of LGC Science Group Holdings Limited in the Global Nucleic Acid Therapeutics CDMO Market
7.2.12.3 Recent Developments
7.2.12.4 Analyst Perspective
7.2.13 Maravai LifeSciences Holdings, Inc.
7.2.13.1 Company Overview
7.2.13.2 Role of Maravai LifeSciences Holdings, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.13.3 Financials
7.2.13.4 Recent Developments
7.2.13.5 Analyst Perspective
7.2.14 Merck KGaA
7.2.14.1 Company Overview
7.2.14.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
7.2.14.3 Financials
7.2.14.4 Recent Developments
7.2.14.5 Analyst Perspective
7.2.15 Nippon Shkubai Co., Ltd
7.2.15.1 Company Overview
7.2.15.2 Role of Nippon Shokubai Co., Ltd in the Global Nucleic Acid Therapeutics CDMO Market
7.2.15.3 Financials
7.2.15.4 Analyst Perspective
7.2.16 ST Pharm
7.2.16.1 Company Overview
7.2.16.2 Role of ST Pharm in the Global Nucleic Acid Therapeutics CDMO Market
7.2.16.3 Financials
7.2.16.4 Recent Developments
7.2.16.5 Analyst Perspective
7.2.17 Thermo Fisher Scientific Inc.
7.2.17.1 Company Overview
7.2.17.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
7.2.17.3 Financials
7.2.17.4 Analyst Perspective

Figure 1: Services Offered by CDMOs
Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 3: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
Figure 4: Global Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
Figure 5: Global Nucleic Acid Therapeutics CDMO Market Segmentation
Figure 6: Global Nucleic Acid Therapeutics CDMO Market: Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
Figure 9: Top-Down Approach (Segment-Wise Analysis)
Figure 10: Significant Number of Collaborations among Market Players in Global Nucleic Acid Therapeutics CDMO Market, 2019-2023
Figure 11: Core CDMO Services
Figure 12: Global Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
Figure 13: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
Figure 14: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
Figure 15: Synthesis Capabilities of Key Companies
Figure 16: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 17: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
Figure 18: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
Figure 19: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
Figure 20: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Chemical Synthesis Method), $Billion, 2023-2033
Figure 21: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Chemical Synthesis Method), 2022-2033
Figure 22: Advantages and Disadvantages of Solid-Phase Oligonucleotide Synthesis
Figure 23: Global Nucleic Acid Therapeutics CDMO Market (Solid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
Figure 24: Advantages and Disadvantages of Liquid-Phase Oligonucleotide Synthesis
Figure 25: Global Nucleic Acid Therapeutics CDMO Market (Liquid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
Figure 26: Global Nucleic Acid Therapeutics CDMO Market (by Product)
Figure 27: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Product), $Billion, 2023-2033
Figure 28: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Product), 2022-2033
Figure 29: Global Nucleic Acid Therapeutics CDMO Market (Standard Nucleic Acid), $Billion, 2022-2033
Figure 30: Global Nucleic Acid Therapeutics CDMO Market (Micro-Scale Nucleic Acid), $Billion, 2022-2033
Figure 31: Global Nucleic Acid Therapeutics CDMO Market (Large-Scale Nucleic Acid), $Billion, 2022-2033
Figure 32: Global Nucleic Acid Therapeutics CDMO Market (Custom Nucleic Acid), $Billion, 2022-2033
Figure 33: Global Nucleic Acid Therapeutics CDMO Market (Modified Nucleic Acid), $Billion, 2022-2033
Figure 34: Global Nucleic Acid Therapeutics CDMO Market (Primers), $Billion, 2022-2033
Figure 35: Global Nucleic Acid Therapeutics CDMO Market (Probes), $Billion, 2022-2033
Figure 36: Global Nucleic Acid Therapeutics CDMO Market (Other Nucleic Acid), $Billion, 2022-2033
Figure 37: Global Nucleic Acid Therapeutics CDMO Market (Other Services), $Billion, 2022-2033
Figure 38: Global Nucleic Acid Therapeutics CDMO Market (by Technology)
Figure 39: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Technology), $Billion, 2023-2033
Figure 40: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Technology), 2022-2033
Figure 41: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), $Billion, 2022-2033
Figure 42: Global Nucleic Acid Therapeutics CDMO Market (Microarray-Based Method), $Billion, 2022-2033
Figure 43: Global Nucleic Acid Therapeutics CDMO Market (by End User)
Figure 44: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by End User), $Billion, 2023-2033
Figure 45: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by End User), 2022-2033
Figure 46: Global Nucleic Acid Therapeutics CDMO Market (Pharmaceutical Companies), $Billion, 2022-2033
Figure 47: Global Nucleic Acid Therapeutics CDMO Market (Academic Institutions), $Billion, 2022-2033
Figure 48: Global Nucleic Acid Therapeutics CDMO Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 49: Global Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
Figure 50: North America Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 51: North America Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
Figure 52: U.S. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 53: Canada Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 54: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 55: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
Figure 56: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 57: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 58: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 59: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 60: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 61: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 62: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 63: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 64: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
Figure 65: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 66: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 67: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 68: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 69: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 70: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 71: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
Figure 72: Funding Activities, January 2018-February 2023
Figure 73: New Offerings, January 2018-February 2023
Figure 74: Mergers and Acquisitions, January 2018-February 2023
Figure 75: Partnerships and Collaborations, January 2018-February 2023
Figure 76: Business Expansions, January 2018-February 2023
Figure 77: Regulatory and Legal Activities, January 2018-February 2023
Figure 78: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
Figure 79: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
Figure 80: Agilent Technologies, Inc: Product Portfolio
Figure 81: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 82: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 83: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 84: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 85: AGC Biologics: Product Portfolio
Figure 86: AGC Biologics: Overall Financials, $Million, 2019-2021
Figure 87: AGC Biologics: Segment Revenues, $Million, 2019-2021
Figure 88: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
Figure 89: Asymchem Inc.: Product Portfolio
Figure 90: Asymchem Inc.: Overall Financials, $Million, 2021-2022
Figure 91: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
Figure 92: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
Figure 93: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
Figure 94: BACHEM: Product Portfolio
Figure 95: BACHEM: Overall Financials, $Million, 2020-2022
Figure 96: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
Figure 97: BACHEM: Net Revenue (by Region), $Million, 2020-2022
Figure 98: BACHEM: R&D Expenditure, $Million, 2020-2022
Figure 99: BioCina: Product Portfolio
Figure 100: CMIC HOLDINGS Co., Ltd.: Product Portfolio
Figure 101: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
Figure 102: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
Figure 103: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
Figure 104: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 105: Codexis, Inc: Product Portfolio
Figure 106: Codexis, Inc: Overall Financials, $Million, 2020-2022
Figure 107: Codexis, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 108: Codexis, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 109: Codexis, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 110: Danaher Corporation: Product Portfolio
Figure 111: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 112: Danaher Corporation: Net Revenue (by Segment), $Million, 2020-2022
Figure 113: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
Figure 114: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 115: Eurofins Scientific: Product Portfolio
Figure 116: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 117: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
Figure 118: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
Figure 119: VGXI, Inc.: Product Portfolio
Figure 120: Kaneka Corporation: Product Portfolio
Figure 121: Kaneka Corporation: Overall Financials, $Million, 2019-2021
Figure 122: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
Figure 123: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 124: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
Figure 125: LGC Science Group Holdings Limited: Product Portfolio
Figure 126: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
Figure 127: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
Figure 128: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
Figure 129: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
Figure 130: Maravai LifeSciences Holdings, Inc.: Product Portfolio
Figure 131: Maravai LifeSciences Holdings, Inc.: Overall Financials, $Million, 2020-2022
Figure 132: Maravai LifeSciences Holdings, Inc.: Segment Revenues, $Million, 2020-2022
Figure 133: Maravai LifeSciences Holdings, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 134: Maravai LifeSciences Holdings, Inc: R&D Expenditure, $Million, 2020-2022
Figure 135: Merck KGaA: Product Portfolio
Figure 136: Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 137: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
Figure 138: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
Figure 139: Merck KGaA: R&D Expenditure, $Million, 2020-2022
Figure 140: Nippon Shokubai Co., Ltd: Product Portfolio
Figure 141: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
Figure 142: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
Figure 143: ST Pharm: Product Portfolio
Figure 144: ST Pharm: Overall Financials, $Million, 2019-2021
Figure 145: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021
Figure 146: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 147: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 148: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 149: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 150: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

Table 1: Global Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
Table 2: Key Questions Answered in the Report
Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
Table 4: Global Nucleic Acid Therapeutics CDMO Market, Key Investment
Table 5: Global Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
Table 7: Advancements in Manufacturing Units of CDMO
Table 8: Companies Offering Standard Nucleic Acid
Table 9: Companies Offering Micro-Scale Nucleic Acid
Table 10: Companies Offering Large-Scale Nucleic Acid
Table 11: Companies Offering Custom Nucleic Acid
Table 12: Companies Offering Modified Nucleic Acid
Table 13: Companies Offering Primers
Table 14: Some of the Companies Offering Probes
Table 15: Companies Offering Other Nucleic Acid
Table 16: Some of the Companies Offering Other Services
Table 17: North America Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Table 18: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
Table 19: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Table 20: Rest-of-the-World Nucleic Acid Therapeutic CDMO Market, Impact Analysis